关于贤丰控股股份有限公司 2024 年度非经营性资金占用及 其他关联资金往来情况的 专项审核报告 深圳广深会计师事务所(普通合伙) 地址 板高编码:粤25 目 录 | 内 容 | 可 -欠 | | --- | --- | | 一、关于贤丰控股股份有限公司 2024 年度非经营性资金占 | 1-2 | | 用及其他关联资金往来情况的专项审核报告 | | | 二、附件:贤丰控股股份有限公司 2024年度非经营性资金 | 3-4 | | 占用及其他关联资金往来情况汇总表 | | 三、会计师事务所及注册会计师执业资质证明 贤丰控股公司管理层根据中国证券监督管理委员会联合公安部、国务院国有 资产监督管理委员会及中国银行保险监督管理委员会发布的《上市公司监管指引 第8号 -- 上市公司资金往来、对外担保的监管要求》和《深圳证券交易所上市 公司自律监管指南第1号 -- 业务办理(2023年12月修订)》的规定编制了后附 的贤丰控股公司2024年度非经营性资金占用及其他关联资金往来情况汇总表(以 下简称"汇总表")。如实编制和对外披露汇总表,并保证其真实性、合法性及 完整性是贤丰控股公司管理层的责任。 我们对汇总表所载资料与 ...

贤丰控股股份有限公司 二〇二四年度 内部控制审计报告 深圳广深会计师事务所(普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） 据生编码 · 曾? 目 录 t - The Press of A 页 次 一、内部控制审计报告 1-2 二、附件:2024年度内部控制自我评价报告 三、会计师事务所及注册会计师执业资质证明 the first 深 圳 广 深 会 计 师 事 务 所(普通合伙) SHENZHEN GUANGSHEN CERTIFIED PUBLIC ACCOUNTANTS (Partnership) 联 系 电 话 : 82127688 地 址 : 深圳市 福田区 滨 河 大 道 5022 号 联 合 广场 B 座 1502 室 内部控制审计报告 广深所证审字[2025]第 010 号 贤丰控股股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了贤丰控股股份有限公司(以下简称"贤丰控股公司")2024年12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制 ...

关于贤丰控股股份有限公司 2023 年度审计报告带强调事项段的无保留审计意见 涉及事项影响已消除的专项审核报告 深圳广深会计师事务所(普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.mof.gov 目 录 内 容 页 1-2 一、2023 年度审计报告带强调事项段的无保留审 计意见涉及事项影响已消除的专项审核报告 二、附件:2023年度审计报告带强调事项段的无 保留审计意见涉及事项影响已消除的专项说明 三、会计师事务所及注册会计师执业资质证明 深 圳 广 深 会 计 师 事 务 所(普通合伙) SHENZHEN GUANGSHEN CERTIFIED PUBLIC ACCOUNTANTS (Partnership) 联系电话:82127688 地址:深圳市福田区滨河大道 5022 号联合广场 B 座 1502 室 关于贤主控股股份有限公司 2023年度审计报告带强调事项段的无保留审计意见 涉及事项影响已消除的专项审核报告 广深所证审字[2025]第011号 贤丰控股股份有限公司全体股东: 我们接受委托,审计了后附的贤丰控股股份有限公司(以下简称"贤丰控股 公司")编 ...

Financial Data and Indicators - The basic earnings per share for 2024 is -0.1045 yuan, showing a 1.32% improvement compared to -0.1059 yuan in 2023 [1] - The net asset per share decreased by 13.19% to 0.79 yuan from 0.91 yuan in the previous year [1] - The operating revenue increased significantly by 400% to 4.4 billion yuan from 0.88 billion yuan in 2023 [1] - The net profit for 2024 is -1.13 billion yuan, a slight improvement of 5.83% from -1.2 billion yuan in 2023 [1] - The return on equity is -12.24%, worsening from -11.06% in the previous year [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 48,173.38 million shares, accounting for 46.71% of the circulating shares, with a decrease of 6,320.79 million shares compared to the previous period [1] - Shenzhen Ansheng Zhihua Investment Partnership (Limited Partnership) has newly entered the top shareholders with 19.21% of total shareholding [2] - Xianfeng Holdings Group Limited reduced its holdings by 4,500 million shares, now holding 11.07% [2] - Several new shareholders have entered the list, including Wei Wei and Zhang Shouchun, with holdings of 2.79% and 2.75% respectively [2] Dividend Distribution - The company has announced no distribution or capital increase for the current period [3]

2025 年 4 月 27 日 贤丰控股股份有限公司 董事会 贤丰控股股份有限公司 关于独立董事 2024 年度独立性评估的专项意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等要求，贤丰控股股份有限公司（以下简称公司）董事会就公 司现任独立董事肖世练、邓延昌、梁融在 2024 年度的独立性情况进行评估并出 具如下专项意见： 经核查现任独立董事肖世练、邓延昌、梁融的任职经历以及签署的相关自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东 公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其 进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》中对独立董事独立性的相关要求。 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （梁融） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"或"贤 丰控股"）的独立董事，根据《上市公司独立董事管理办法》及《独立董事工作 制度》的相关规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人梁融，律师执业经验逾10年，曾任北京市盈科（深圳）律师事务所合伙 人律师、万商天勤（深圳）律师事务所合伙人律师，现任广东知恒律师事务所股 权高级合伙人，兼任深圳市长盈精密技术股份有限公司（300115.SZ）独立董事、 深圳市一搏科技股份有限公司（301366.SZ）独立董事，2020年5月21日起任公司 独立董事。 本人不在贤丰控股担任除独立董事外的其他职务，经自查，与贤丰控股及其 主要股东不存在直接或间接利害关系，或者其他可能影响本人独立性的关系，满 足有关规定中对于出任贤丰控股独立董事所应具备的独立性要求。 二、年度履职概况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席2次，以线上会议方 式出席2次；公司召开董事会会议13次，本人以现场方式出席4次，以线上会议方 式出席9次；均无委托出 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （肖世练） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"或 "贤丰控股"）的独立董事，根据《上市公司独立董事管理办法》及《独立董 事工作制度》等相关规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人肖世练，博士研究生学历，中国注册会计师，国际注册内部审计师。 曾供职于广州海关、普华永道会计师事务所、安永会计师事务所、广州农村商 业银行股份有限公司、粤港澳大湾区产融投资有限公司，现任职于广州健博企 业服务有限公司，兼任蜂助手股份有限公司（301382.SZ）、深圳市佳士科技股 份有限公司（300193.SZ）、深圳市新涛新材料股份有限公司、深圳市皓吉达电 子科技股份有限公司的独立董事，2023年10月9日起任公司独立董事。 本人不在贤丰控股担任除独立董事外的其他职务，与贤丰控股及其主要股 东不存在直接或间接利害关系，或者其他可能影响本人独立性的关系，满足有 关规定中对于出任贤丰控股独立董事所应具备的独立性要求。 二、年度履职情况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席1次，以线上 ...

贤丰控股股份有限公司 2024年度独立董事述职报告 （邓延昌） 本人作为贤丰控股股份有限公司（以下简称"公司"、"上市公司"、"贤 丰控股"）的独立董事，根据《上市公司独立董事管理办法》以及《独立董事工 作制度》的规定，现将本人2024年度工作情况汇报如下： 一、基本情况 本人邓延昌，教授级高级工程师，曾任辽宁有色地质勘查总院院长、国家危 机矿山接替资源勘查监审专家、银泰黄金股份有限公司（000975.SZ）独立董事。 2020年1月23日起任公司独立董事，无其他兼职情况。 本人不在贤丰控股担任其他职务，与贤丰控股及其主要股东不存在直接或间 接利害关系，或者其他可能影响本人独立性的关系，满足有关规定中对于出任贤 丰控股独立董事所应具备的独立性要求。 二、年度履职概况 （一）出席董事会和股东大会会议情况 2024年度，公司召开股东大会4次，本人以现场方式出席3次，以线上会议方 式出席1次；公司召开董事会会议13次，本人以现场方式出席5次，以线上会议方 式出席8次；均无委托出席和缺席情形，本人对提交董事会审议的各项议案均表 示同意，无反对或弃权情形。 （五）与中小投资者沟通交流情况 （二）参与董事会专门委员会、独 ...

Financial Performance - The company's operating revenue for 2024 was ¥440,478,600.49, representing a 400.31% increase compared to ¥88,040,600.80 in 2023[20]. - The net profit attributable to shareholders for 2024 was -¥113,006,166.29, a slight improvement of 5.92% from -¥120,115,833.29 in 2023[20]. - The net cash flow from operating activities for 2024 was -¥479,582,657.09, a significant decline of 818.32% compared to -¥52,224,007.16 in 2023[20]. - Total assets at the end of 2024 reached ¥1,470,823,932.83, an increase of 23.33% from ¥1,192,593,505.11 at the end of 2023[20]. - The company's net assets attributable to shareholders decreased by 20.44% to ¥820,299,187.95 at the end of 2024 from ¥1,031,077,872.65 at the end of 2023[20]. - Non-recurring gains for 2024 amounted to ¥18,295,621.80, compared to ¥12,380,814.32 in 2023, primarily from asset disposals and government subsidies[25][26]. - The company's basic earnings per share for 2024 was -¥0.1045, a slight improvement of 1.32% from -¥0.1059 in 2023[20]. - The total amount of accounts receivable confirmed during the reporting period was ¥6,737.57 million[52]. - The company's total operating costs reached ¥405,224,302.75, a significant increase of 688.43% compared to the previous year[55]. - The total distributable profit for the reporting period was -419,349,894.07 CNY, indicating a loss[130]. Business Operations - The main business operations include veterinary vaccines, copper-clad laminates, and animal nutrition (feed) as of the report date[18]. - The company has strategically exited the fine enameled wire business as of the end of Q3 2022, focusing on its new business segments[18]. - The animal nutrition business has seen monthly sales growth due to increased market demand, despite being in its early development stage with only 2 months of operational experience[34]. - The company has established a comprehensive procurement management system to reduce costs while ensuring stable quality, adapting to market changes[33]. - The company is focusing on enhancing product quality, optimizing sales channels, and improving production capacity to better its profitability[36]. - The company has implemented a strategic transformation to improve operational conditions and expand its business scope, aiming to eliminate delisting risk warnings[43]. - The company has upgraded its production facilities to meet the latest GMP standards, ensuring the safety, effectiveness, and quality stability of its vaccines[39]. - The company aims to position itself as a "vaccine process expert and disease solution expert," focusing on high-quality vaccine production and comprehensive technical services for livestock farms[40]. Market Conditions - The company reported a significant decline in the pig farming industry, with a 3.31% decrease in the national pig slaughter volume to 703 million heads in 2024[28]. - The average price of pigs showed signs of recovery starting in Q2 2024, but this did not translate to improved conditions for upstream animal health companies[28]. - The company faced intense competition in the animal health sector, with price wars becoming the norm due to prolonged payment cycles and low bidding standards[28]. - The pig vaccine business has faced increased competition, leading to a decline in product gross margins and longer accounts receivable periods[33]. - The feed industry is evolving towards green and intelligent production in response to environmental policies and customized demands[29]. Research and Development - The company has established a comprehensive innovation system through collaborations with top research institutions, resulting in 9 new veterinary drug registration certificates and 33 invention patents[37]. - A new live vaccine for pseudorabies (JS-A1 strain) developed in collaboration with the Chinese Academy of Agricultural Sciences received a new veterinary drug certificate in November 2024, marking it as the first of its kind in China[38]. - The company has a total of 31 vaccine products registered, including 15 for pigs and 16 for poultry, and continues to enhance its product offerings to strengthen market competitiveness[39]. - R&D investment increased by 28.89% to ¥15,564,041.87 in 2024, while the proportion of R&D investment to operating revenue decreased to 3.53% from 13.72%[63]. - The number of R&D personnel rose by 29.55% to 57 in 2024, with a significant increase in master's degree holders by 41.18%[63]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations and decision-making processes[97]. - The board of directors consists of 7 members, including 3 independent directors, meeting regulatory requirements for governance[98]. - The company has implemented a strategic plan to enhance market competitiveness and is committed to ongoing innovation in response to industry trends and customer needs[90]. - The company has established a comprehensive investor relations management system to enhance communication and ensure investors' rights are protected[99]. - The company has implemented a public opinion response management system to effectively handle various public sentiments impacting stock prices and business reputation[99]. Environmental Compliance - The company has complied with all relevant environmental protection laws and regulations during its operations[141]. - The total investment in environmental protection measures for 2024 by Shiji Biological amounted to CNY 268,360, including wastewater treatment agents, environmental taxes, hazardous waste disposal, and equipment maintenance[150]. - The companies are actively complying with local environmental regulations and have established measures to manage and monitor their emissions[145]. - Shiji Biological successfully executed its environmental self-monitoring plan during the reporting period without any exceedances[147]. Shareholder Relations - The company reported a profit distribution plan of 0 cash dividends and 0 bonus shares per 10 shares for all shareholders[5]. - The company did not propose any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[132]. - The company plans to maintain its share repurchase strategy in 2024 but will not distribute cash dividends or issue bonus shares[132]. - The participation rate for the 2024 first extraordinary shareholders' meeting was 40.17%[102]. - The company completed the repurchase of 101,720,721 shares, accounting for 8.96% of the total share capital, which is treated as a cash dividend[128]. Risks and Challenges - The company has faced a decline in its veterinary vaccine business for two consecutive years, with sales at a low level, indicating high market competition risks[89]. - The company is addressing raw material price volatility risks, which could significantly impact costs and profits, by closely monitoring market trends and exploring strategic supplier relationships[92]. - The company has a high customer concentration in its feed business, which poses risks if customer relationships deteriorate; it plans to actively develop new markets to mitigate this risk[91]. - The company emphasizes the importance of managing accounts receivable to prevent bad debt risks as its business scales up, despite currently having a low bad debt rate[93]. Audit and Compliance - The company received a standard unqualified audit report for the 2024 fiscal year, with audited revenue exceeding 300 million yuan[188]. - The 2023 audit report highlighted concerns regarding the controlling shareholder's bankruptcy proceedings, which have since been addressed, ensuring no significant impact on the company's operations[187]. - The company identified and corrected significant internal control deficiencies related to revenue recognition and inflated income from subsidiary Chengdu Shiji Bio-Pharmaceutical Co., Ltd., with corrections made prior to the annual report[189][190]. - The company has implemented measures to strengthen internal controls, including revising organizational structures and enhancing management oversight to prevent future issues[191].

[Key Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) In Q1 2025, the company achieved significant revenue and net profit growth, primarily from new businesses and asset disposal, despite negative core business profitability and operating cash flow [Key Accounting Data and Financial Indicators](index=1&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) Key Financial Indicators for Q1 2025 | Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 294,682,212.25 | 16,649,876.31 | 1,669.88% | | Net Profit Attributable to Shareholders (RMB) | 14,210,084.66 | -153,837.59 | 9,337.07% | | Net Profit Attributable to Shareholders (Excl. Non-recurring) (RMB) | -3,456,542.95 | -8,687,680.76 | 60.21% | | Net Cash Flow from Operating Activities (RMB) | -70,936,119.71 | 10,809,362.41 | -756.25% | | Basic Earnings Per Share (RMB/share) | 0.0138 | -0.0001 | 13,900.00% | | Total Assets (RMB) | 1,475,871,009.94 | 1,470,823,932.83 | 0.34% (vs. end of prior year) | | Total Equity Attributable to Shareholders (RMB) | 835,229,144.34 | 820,299,187.95 | 1.82% (vs. end of prior year) | [Non-recurring Gains and Losses Items and Amounts](index=1&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%20%E9%9D%9E%E5%B8%B8%E9%87%91%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) - Total non-recurring gains and losses for the current period amounted to **RMB 17.67 million**, a key factor for the company's profitability, with non-current asset disposal gains contributing **RMB 18.49 million**, primarily from the sale of Zhuhai factory land and technology contract transfer[4](index=4&type=chunk)[5](index=5&type=chunk) Details of Non-recurring Gains and Losses Items | Item | Amount for Current Period (RMB) | Description | | :--- | :--- | :--- | | Non-current asset disposal gains and losses | 18,488,785.48 | Primarily due to partial completion of Zhuhai factory land transfer and Chengdu Shiji technology contract transfer | | Government grants recognized in current profit/loss | 721,156.49 | - | | Other non-operating income/expenses and fair value changes | 38,032.59 | - | | Impact on minority interests (after tax) | 1,581,346.95 | - | | **Total** | **17,666,627.61** | **--** | [Changes and Reasons for Key Accounting Data and Financial Indicators](index=2&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) - Significant increases in operating revenue and costs (**1669.88%** and **3624.62%** respectively) were primarily driven by the newly added copper-clad laminate and feed businesses in the current period[6](index=6&type=chunk) - Research and development expenses increased by **118.63%** year-on-year, mainly due to increased R&D investment in Gaoshuo Hangyu's copper-clad laminate business[6](index=6&type=chunk) - Net cash flow from operating activities significantly decreased by **756.25%**, primarily impacted by the credit terms of subsidiary Gaoshuo Hangyu[7](index=7&type=chunk) - Net cash flow from investing activities turned positive, increasing by **159.72%**, mainly due to the recovery of investment funds and redemption of wealth management products in the current period[7](index=7&type=chunk) [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) As of the reporting period end, the company had 28,097 common shareholders, with the top two holding over 30%, and the second largest shareholder's entire stake is pledged and frozen [Common Shareholder Holdings](index=3&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%20%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) - As of the end of the reporting period, the total number of common shareholders was **28,097**[9](index=9&type=chunk) Top Two Shareholders' Holdings | Shareholder Name | Shareholding Percentage (%) | Number of Shares Held | Share Status | | :--- | :--- | :--- | :--- | | Shenzhen Ansheng Zhihe Investment Partnership (Limited Partnership) | 19.18% | 198,140,000 | N/A | | Xianfeng Holdings Group Co., Ltd. | 11.05% | 114,152,000 | Pledged 69,000,000; Frozen 114,152,000 | - The second largest shareholder, Xianfeng Holdings Group Co., Ltd., has **114,152,000** shares (**11.05%** of total share capital) fully frozen, with **69,000,000** shares pledged[9](index=9&type=chunk) [Other Significant Matters](index=4&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) The company disclosed significant matters including office address changes, asset transfer progress, and a CSRC administrative penalty pre-notification, which may impact operations and stock price Significant Matters Disclosed During the Reporting Period | Overview of Significant Matter | Disclosure Date | | :--- | :--- | | Change of Office Address | 2025年01月24日 | | Progress and Extension of Land Use Rights and Above-Ground Building Ownership Transfer | 2025年02月13日, 2025年03月22日 | | Receipt of Pre-notification of Administrative Penalty | 2025年03月24日 | [Quarterly Financial Statements](index=4&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the unaudited Q1 2025 consolidated financial statements, showing slight asset growth, liability decrease, significant revenue and profit turnaround from new businesses and non-recurring gains, and deteriorating operating cash flow despite improved investing and financing cash flows - The company's first quarter report is unaudited[19](index=19&type=chunk) [Consolidated Balance Sheet](index=4&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) Key Balance Sheet Items Changes | Item | Period-end Balance (RMB) | Period-start Balance (RMB) | | :--- | :--- | :--- | | Total Assets | 1,475,871,009.94 | 1,470,823,932.83 | | Total Liabilities | 589,800,602.42 | 599,813,408.35 | | Total Equity Attributable to Parent Company Owners | 835,229,144.34 | 820,299,187.95 | [Consolidated Income Statement](index=6&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Key Income Statement Items | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | I. Total Operating Revenue | 294,682,212.25 | 16,649,876.31 | | II. Total Operating Costs | 293,560,627.82 | 25,970,020.19 | | III. Operating Profit | 14,309,681.85 | -1,911,435.81 | | V. Net Profit | 14,340,011.31 | -1,511,035.74 | | Net Profit Attributable to Parent Company Owners | 14,210,084.66 | -153,837.59 | [Consolidated Cash Flow Statement](index=8&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Key Cash Flow Statement Items | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -70,936,119.71 | 10,809,362.41 | | Net Cash Flow from Investing Activities | 16,264,345.28 | -27,236,522.83 | | Net Cash Flow from Financing Activities | 14,437,996.31 | -5,022,735.16 | | Net Increase in Cash and Cash Equivalents | -40,171,026.63 | -21,117,345.36 |